Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson’s disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is being studied for its effect on ...

Unilateral focused ultrasound ablation of the internal segment of globus pallidus has reduced motor symptoms of Parkinson’s disease in open-label studies. We randomly assigned, in a 3:1 ratio, ...

Roche and Prothena today announced topline results from the first half of their Phase 2 trial of the α-synuclein antibody prasinezumab. Results were negative on the MDS-UPDRS, the primary outcome ...

Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population. Parkinson’s patients with substantial cognitive decline exhibited a very ...